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ABSTRACT  
Objective: To investigate the effect of lactose and talcum, and also the tablet size and hydrodynamic force on the physical 
appearance and the release of indomethacin from PEG matrix prepared by fusion and mold technique.  
Method: The drug dissolution from the developed matrix tablets was carried out in phosphate buffer pH 6.2 using dissolution 
apparatus Type 1. Least square fitting the experimental dissolution data to the mathematical expressions (power law, first order, 
Higuchi7s and zero order) was performed. SEM and DSC studies were conducted to characterize physical appearance of the 
system.  
Results: An addition of lactose and talcum diminished the drug dissolution from tablets. The higher amount of carrier in the 
case of larger tablet promoted the drug release. The drug release from matrix was enhanced as the rotational speed was 
increased. DSC study indicated the amorphous state of drug in the carrier. SEM photomicrograph indicated the drug diffusion 
outward through the porous network.  
Conclusion: Because of the diminishment of the PEG amount, the incorporation of diluents, such as talcum and lactose, or the 
decrease in the size of tablet diminished the drug dissolution from PEG matrix. Curve fitting indicated the drug release kinetics 
primarily as Fickian diffusion and near zero-order kinetic from the matrix systems containing talcum and lactose respectively. 
Keywords: formulation variables, physicochemical, matrix tablet, polyethylene glycol  
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Introduction 
§Sustained release dosage forms are formulated to 
provide the drug available over an extended period of 
time following administration. In practical terms, an oral 
sustained release dosage form should allow a reduction 
in dosing frequency as compared to its conventional 
dosage form. Matrix tablet is the popular sustained 
release dosage form regarding its effectiveness for 
controlling drug release and economical manufacturing 
process. The matrix device consists of drug dispersed 
homogenously throughout the polymer or wax matrices.
1 
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Because of some limitation for sustaining the poorly 
water-soluble drugs, the dissolution enhancement of 
these drugs before using polymeric matrix to prolong the 
drug release is challenging. Solid dispersion of 
medicaments in an inert hydrophilic carrier in the solid 
state could increase the apparent solubility or enhance 
the bioavailability of poorly water-soluble drugs.
2,3
 Some 
polymers such as polyethylene glycol (PEG) and 
polyvinylpyrrolidone have been extensively used as 
carriers for dispersions due to their low melting point and 
hydrophilic nature.
4 
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Solid PEG is a wax-like material which can be molten 
and then molded into any desired form. Polyethylene 
glycol with all grades are soluble in water and miscible in 
all proportions with other polyethylene glycols. Aqueous 
solutions of higher-molecular-weight grades of PEG may 
form gels. Liquid polyethylene glycols are soluble in 
acetone, alcohols, benzene, glycerin and glycols. Solid 
polyethylene glycols are soluble in acetone, dichloro-
methane, ethanol and methanol. They are slightly soluble 
in aliphatic hydrocarbons and ether.  
Polyethylene glycols (PEGs) are widely used in a 
variety of pharmaceutical formulations including 
parenteral, topical, ophthalmic, oral and rectal pre-
parations.
4 
Polyethylene glycols are stable, hydrophilic 
substances that are essentially nonirritant to the skin. 
Polyethylene glycols can also be used to enhance the 
aqueous solubility characteristics of poorly soluble 
compounds.
5
 Liquid grades (PEG 200 - 600) are in the 
form of clear, colorless or slightly yellow-colored, viscous 
liquids. PEG with grades of 6000 or above are available 
as free-flowing milled powders that can be used as 
excipient for tabletting. Particularly, PEG 4000 or 6000 
has been employed as a carrier for increasing the 
dissolution rate of several poorly water?soluble drugs, 
such as itraconazole
6
, diclofenac
7 
and rofecoxib
8
. 
Therefore, PEG 4000 combined with PEG 400 was used 
in this investigation as carrier for indomethacin which is a 
poorly water-soluble drug.  
Hydrophilic matrix has become extremely popular in 
controlling the release rate of drugs from solid dosage 
forms. Xanthan gum is a natural polysaccharide which is 
one of the important industrial biopolymers. The 
polysaccharide B-1459, or xanthan gum, produced by the 
bacterium Xanthomonas campestris NRRL B-1459 was 
extensively studied because of its properties that would 
allow it to supplement other known natural and synthetic 
water-soluble gums.
9
 Xanthan gum has been widely used 
in oral and topical formulations, cosmetics and food as 
thickening agent.
10 
Xanthan gum has been used as an 
effective excipient for sustained release dosage forms 
since it can form the gel and retard the drug release and 
sometimes provides time-dependent release kinetics.
11,12
 
Because of its capability of producing a dominant 
increased viscosity with a very small quantity, it is a 
potential candidate substance for prolongation of drug 
release. 
In this study, indomethacin solid dispersion tablets 
were prepared with melting and mold method using 7:3 
PEG4000 : PEG 400 as inert carrier and xanthan gum as 
hydrophilic polymer to obtain the model formulation 
having functions of both the drug solubility enhancement 
and the extended release properties. Effect of tablet size, 
diluents and hydrodynamic force on the physical 
appearance and in vitro drug-release behavior of the 
systems were investigated. 
 
 
Material and methods 
Materials 
Indomethacin (Batch No. 050814, China National 
Chemical Imp. Exp., China) was used as received. 
Polyethylene glycol 4000 (lot no. 504907) and 
polyethylene glycol 400 (lot no. PO76049) were 
purchased from P.C. Drug Center Co., Ltd., Thailand. Di-
sodium hydrogen orthophosphate (lot no. 405300, Ajax 
Finechem, Australia), hydrochloric acid (lot no. E23W60, 
J.T. Baker, USA), potassium dihydrogen orthophosphate 
(lot no. E23W60, Ajax Finechem, Australia), sodium 
chloride (lot no. AF 407256, Ajax Finechem, Australia), 
sodium hydroxide (lot no. AF 310204, Ajax Finechem, 
Australia) were used to prepare the dissolution fluids. 
Xanthan gum (Xantural 75

) (lot no. 01-100, CP Kelco 
U.S., Inc. USA.) was used as received. Talcum (lot no. M 
512312, Ajax Finechem, Australia) and lactose (lot no. 
080200 A 9249, Auckland, New Zealand) were passed 
through the 80 mesh sieve before use. 
 
Preparation of Tablet by Mold Technique 
Tablets containing 75 mg indomethacin and 5% 
xanthan gum in 7:3 PEG 4000:PEG 400 were prepared 
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with the melting and mold technique. The tablet was 
prepared by melting PEG 4000 on the water bath and 
mixed with PEG 400, drug and polymer, respectively, 
and then the mixtures were poured into the stainless 
steel mold with diameters of 8, 12 and 16 mm. The effect 
of diluents such as, lactose and talcum (15, 25, 35, 45, 
55% w/w), on the physical appearance and drug release 
from matrix tablet were investigated. Tablets of about 
0.87 g containing 75 mg indomethacin, 5% xanthan gum 
and different amount of talcum or lactose in 7:3 PEG 
4000:PEG 400 were prepared with the melting and mold 
technique using the stainless steel mold with diameter of 
12 mm. as described above. The photographs of 
stainless steel molds with different diameters are shown 
in Figure 1.  
 
 
  
Diameter = 8 mm 
 
  
Diameter = 12 mm 
 
  
Diameter = 16 mm 
 
Figure 1 Stainless steel mold with different diameters. 
 
 
Evaluation of Physical appearance of Prepared Tablet 
The hardness of the tablets was determined using a 
hardness tester (Pharmatest, USA). The tablet thickness 
and diameter were measured using a thickness tester 
(Teclock, Japan). A test of drug release was undertaken 
in 900 mL phosphate buffer pH 6.2 using a dissolution 
apparatus (Erweka DT 70, Germany) with the basket 
method at 100 rpm. Samples were collected at specific 
time intervals and assayed by a UV-Vis spectro-
photometer (Perkin-Elmer, Germany) at a wavelength of 
323 nm (Ohara et al., 2005). During the drug release 
studies, the tablets were observed for physical integrity. 
Drug release from these tablets was compared to that of 
capsules containing 75-mg indomethacin powder.  
 
Dissolution Profile Fitting 
Least square fitting the experimental dissolution data 
(cumulative drug release>5% and up to 80%) to the 
mathematical equations (power law, first order, Higuchi7s 
and zero order) was carried out using a nonlinear 
Thai Pharmaceutical and Health Science Journal, Vol. 3 No. 3, Sep. – Dec. 2008  319 
computer programme, Scientist for Windows, version 2.1 
(MicroMath Scientific Software, Salt Lake City, UT, USA). 
The coefficient of determination (r
2
) was used to indicate 
the degree of curve fitting. Goodness-of-fit was also 
evaluated using the Model Selection Criterion (MSC)
13
, 
given below.  
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Where Yobsi and Ycali are observed and calculated 
values of the i-th point, respectively, and wi is the weight 
that applies to the i-th point, n is number of points and p 
is number of parameters. 
 
Differential Scanning Calorimetry (DSC) 
The DSC curves of drug, PEG 4000, PEG 400, 
xanthan gum, lactose, talcum, tablet containing PEG 
4000:PEG 400 and tablet containing drug and 35% 
talcum or lactose were obtained using differential 
scanning calorimetry (DSC) (Pyris Sapphrie DSC, 
Standard 115V, Perkin Elmer instruments, Japan). The 
experiment was done in non-hermetically sealed 
aluminium pans; the heating rate was 10 °C/min and 
using nitrogen as purge gas (20 mL/min). Each 
substance was individually tested as received while the 
sample from the tablets was cut and ground with mortar 
and pestle before test. Samples of approximately 5 mg 
were weighed into aluminium pans. The heating range of 
25 ? 300 °C was used for each substance and the 
heating range of -30 - 70°C with reverse run was used 
for the samples prepared from the tablets.  
 
Determination of Surface Topography of Tablets 
The surface topography of the prepared matrix tablet 
was determined using scanning electron microscope 
(SEM) (Maxim 200 Camscan, Cambridge, England). 
Samples after dissolution test were freeze-dried for 24 
hrs to dry and to avoid the collapse of porous structures. 
The samples were stuck on a metal stub using carbon 
double adhesive and sputter-coated with gold before test. 
Micrographs were taken with a scanning electron 
microscope operated at an accelerating voltage of 20 
KeV.  
 
Results and Discussions  
The Physical Appearance of Matrix Tablets 
Tablet was very hard and difficult to remove from 
stainless steel mold as the high amount PEG 4000 was 
used, but tablet containing high amount of PEG 400 was 
too soft. Hardness of tablet was increased as the amount 
of PEG4000 was increased because the amount of solid 
polyethylene glycol such as PEG 4000 was higher in the 
system. System comprising 70:30 PEG4000:PEG400 
was chosen as carrier for tablet since the tablet prepared 
by mold technique with this system could be easily 
removed from the mold and had suitable hardness for 
tablet dosage form. The hardness of larger tablet was 
dominantly higher than that of smaller tablets (Table 1). 
In addition, the incorporated 5% xanthan gum increased 
the tablet hardness. Most remarkable properties of 
xanthan gum were its capability of producing a large 
increased viscosity with a very small quantity of gum.
14,15
 
Xanthan solutions are highly viscous even at low polymer 
concentrations. This property is useful in many industrial 
applications, especially in the food industry where 
xanthan is used as a thickener, and to stabilize 
suspensions and emulsions. Xanthan gum should act as 
binder in this system and promoted the hardness of the 
prepared tablets. Apparently, the hardness of tablet 
containing talcum and lactose was increased as the 
amount of these diluents was increased (Tables 2 - 3). 
Mater et al (2008)
16 
found that incorporated lactose 
caused an increase of the hardness of the tablet 
prepared with compression method.  
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Table 1 Physical appearance of 75-mg indomethacin tablet with and without 5% w/w xanthan gum in 
70:30 PEG 4000:PEG 400 prepared using mold with different diameters.  
  Physical appearance 
Mold diameter 
(mm) 
Amount of 
xanthan gum 
(% w/w) 
Weight ± S.D.  
(g) (n = 20) 
Thickness ± S.D. 
(mm) (n = 10) 
Diameter ± S.D.  
(mm) (n = 10) 
Hardness ± S.D.  
(Newton; N) (n = 10) 
8 0 0.8912 ± 0.0146 6.53 ± 0.03 8.01± 0.02 14.33 ± 0.79 
8 5 0.8819 ± 0.0108 6.55 ± 0.02 8.02 ± 0.02 14.49 ± 1.67 
12 0 0.8949 ± 0.0225 6.66 ± 0.09 11.97 ± 0.02 16.46 ± 1.41 
12 5 0.8833 ± 0.0140 6.57 ± 0.03 12.02 ± 0.03 18.41 ± 1.55 
16 0 0.8707 ± 0.0194 6.58 ± 0.10 16.01 ± 0.02 29.36 ±1.79 
16 5 0.8954 ± 0.0252 6.58 ± 0.09 16.89 ± 0.03 40.87 ± 1.15 
 
 
Table 2 Physical appearance of 75-mg indomethacin tablets containing 5% w/w xanthan gum and different 
amounts of talcum in 70:30 PEG 4000:PEG 400 prepared using mold with diameter of 12 mm.  
Physical appearance 
Amount of talcum 
(%) 
Weight ± SD (g) 
(n = 20) 
Thickness ± S.D. 
(mm) (n = 10) 
Diameter ± S.D. (mm) 
(n = 10) 
Hardness ± S.D. 
(Newton; N) (n = 10) 
15 0.8751 ± 0.0312 6.75 ± 0.22 12.01 ± 0.03 18.8 ± 5.67 
25 0.8809 ± 0.0124 6.72 ± 0.23 12.03 ± 0.02 24.3 ± 4.75 
35 0.8785 ± 0.0501 6.83 ± 0.25 12.02 ± 0.03 35.6 ± 4.27 
45 0.8839 ± 0.0632 6.75 ± 0.28 12.05 ± 0.02 39.7 ± 3.62 
55 0.8860 ± 0.0211 6.72 ± 0.22 12.03 ± 0.04 47.3 ± 4.27 
 
 
Table 3 Physical appearance of 75-mg indomethacin tablets containing 5% w/w xanthan gum and different 
amounts of lactose in 70:30 PEG 4000:PEG 400 prepared using mold with diameter of 12 mm.  
Physical appearance 
Amount of lactose 
(%) 
Weight ± S.D.  
(g) (n = 20) 
Thickness ± S.D.  
(mm) (n = 10) 
Diameter ± S.D. 
(mm) (n = 10) 
Hardness ± S.D. 
(Newton; N) (n = 10) 
15 0.8834 ± 0.0234 6.78 ± 0.19 12.05 ± 0.02 20.3 ± 4.67 
25 0.8789 ± 0.0312 6.82 ± 0.31 12.08 ± 0.02 26.4 ± 5.75 
35 0.8704 ± 0.0237 6.75 ± 0.25 12.06 ± 0.02 34.5 ± 3.27 
45 0.8756 ± 0.0187 6.82 ± 0.26 12.04 ± 0.02 37.7 ± 2.92 
55 0.8821 ± 0.0256 6.79 ± 0.21 12.05 ± 0.02 46.7 ± 3.17 
 
 
In Vitro Drug Release Studies 
Drug release from tablet without an addition of xanthan 
gum was faster than that containing xanthan gum (Fig. 
2). This was because the former tablet contained PEG 
as carrier for increasing the solubility of indomethacin 
and there was no hydrophilic polymer to form gel for 
retarding the drug dissolution. Polyethylene glycols 
(PEGs) are one of the most widely used carriers to 
prepare solid dispersions due to their low melting point 
and their ability to provide the hydrophilic environment to 
enhance drug solubility.
4
 An enhancement of dissolution 
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rate of hydrocortisone and prednisolone has been 
reported by means of the fusion method, using sorbitol, 
sucrose, or PEG 6000 as carriers. The carriers are 
melted at elevated temperature and the drugs are 
dissolved in molten carriers.
17,18
 Drug release from 
tablets prepared by solid dispersion method was 
apparently faster than that from capsules containing only 
75-mg indomethacin. This result demonstrated the 
efficacy of PEG matrix for increasing the dissolution of 
indomethacin. Xanthan gum increased the viscous gel 
layer around the matrix core. In addition, the synergism 
attributed to the intermolecular hydrogen-bonding 
between acid group of indomethacin and OH-group of 
xanthan gum could occur.
19
 High swelling capacity and 
gel formation of xanthan gum could retard the release of 
dissolved drug from the matrix. Relationship between 
drug release and the gel formation of polymer was 
previously reported by Fu et al (2004).
20
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Figure 2  Effect of tablet size on drug release from tablet containing 5% xanthan gum compared with that of 
tablet without xanthan gum in phosphate buffer pH 6.2 (n = 3). 
 
 
Effect of mold size and xanthan gum on drug 
release 
Xanthan gum could enhance the viscous gel layer 
around the matrix core. Therefore, drug release from 
tablets containing 5% xanthan gum was slower than that 
of tablets without xanthan gum given the same tablet 
size (Fig. 2). The total amount of PEG 4000 and PEG 
400 was increased as the tablet size was increased 
since the amount of drug was fixed at 75 mg per tablet. 
Therefore the drug release from the large tablet was the 
fastest among the three sizes of the tested tablets. 
Carriers enhanced the solubility of poorly water-soluble 
drug by enhancement of the wettability and dispersibility 
of drug because the possible formation of a metastable 
dispersion could promote a greater solubility of drug in a 
faster dissolution rate.
21
 
Effect of talcum and lactose on drug release 
Incorporation of talcum into xanthan gum matrix 
minimized the drug dissolution and retarded the drug 
release in phosphate buffer pH 6.2 (Fig. 3) since the 
enhanced amount of talcum decreased the amount of 
carriers. This result indicated that the amount of carrier 
significantly affected the drug release. Similar result has 
been mentioned by Uhumwangho et al (2007)
22
 who 
investigated the effect of hydrophobic agents (i.e., talc or 
magnesium stearate) on the drug release profiles of the 
melt granulations. This mentioned investigation thus 
sought for a simple approach for effectively modifying 
drug release from granules. Such granules could 
ultimately be encapsulated or tableted for multi-unit dose 
applications. The release rates of paracetamol powder 
from the melt granules were retarded after the 
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incorporation of a hydrophobic agent particularly while 
the talc or magnesium stearate contents were more than 
30%w/w. Pawar et al (2004)
23
 described the ibuprofen-
talc agglomerates prepared by using dichloromethane-
water as the crystallization system. The incorporated 
talcum retarded the rate of water penetration and 
reduced the rate of disentanglement of the polymer. 
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Figure 3 Drug release profiles of tablet containing 5% xanthan gum and different amount of talcum in 
phosphate buffer pH 6.2 (n = 3). 
 
 
Typically, lactose should increase the tablet porosity 
and stimulate the water penetration into the inner parts of 
the matrix. We expected to increase the drug release 
from xanthan gum matrix by incorporating hydrophilic 
filler, such as lactose. However, after adding different 
amounts of lactose into xanthan gum matrix, all tablets 
exhibited percent drug release less than 40% as 
presented in Fig. 4. The drug release decrement for 
tablet containing different amount of lactose was due to a 
diminishment of drug carrier amount. Similar result has 
been mentioned by Perissutti et al (2001)
24
 for utilizing a 
ram extruder to prepare directly a fast release dosage 
form of carbamazepine with uniform shape and density, 
comprising polyethylene glycol 4000 as a low melting 
binder. They concluded that an addition of lactose in this 
system reduced the dissolution rate.  
  
Effect of hydrodynamic force on drug release 
The rate of indomethacin release at 150 rpm rotational 
speed was faster than that at 100 rpm, 50 rpm and 25 
rpm, respectively (Fig. 5). This was due to more rapid 
erosion of matrix at higher stirring rates because of the 
increased rate of detachment of polymer chains away 
from the matrix surface. This led to the thinner layer of 
gel forming at surface of the dosage form at higher 
agitation rate.
25
 Release rate of nitrendipine from 
hydroxypropylmethylcellulose phthalate (HP-55) micro-
spheres was increased as the rotational speed of the 
paddle was increased.
26
 The release of diclofenac 
sodium from lipophilic matrix tablets in phosphate buffer 
solution pH 5.8 increased with higher rotation speed.
27
 
Similar result has been reported for the release 
increment of chlorpheniremine maleate from HPMC 
matrix tablet with increasing rotational speed.
28
 This 
study demonstrated that hydrodynamic stress had an 
effect on dissolution rate, mass transfer rate, and film 
thickness underlying the dissolution process. As the 
stirring speed was excessive, the stagnant boundary 
layer effect was no longer the rate-limiting step in drug 
transport.
12,29
 In addition, an increase of mass transfer 
rate and a decrease in film thickness as the increment of 
basket rotation speed has been reported.
30 
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Figure 4 Drug release profiles of tablet containing 5% xanthan gum and different amount of lactose in 
phosphate buffer pH 6.2 (n = 3). 
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Figure 5 Effect of rotational speed of basket on drug release from tablet containing 75 mg 
indomethacin and 5% xanthan gum in phosphate buffer pH 6.2 (n = 3). 
 
 
The differential scanning calorimetry (DSC) 
Indomethacin, PEG 4000 and PEG 400 exhibited the 
endothermic peak at 161.4 °C, 58.9 ºC and 58.2 °C, 
respectively (data not shown). Xanthan gum and 7:3 
PEG 4000:PEG 400 showed the melting peak at 72.5 °C 
and 47.5 °C, respectively (Fig. 6). Talcum did not exhibit 
the endothermic peak since it is an inert inorganic 
substance with a high melting point. The DSC curve of 
lactose exhibited two endothermic peaks. The first 
endothermic corresponded to the loss of water in crystal 
lattice and the second endothermic peak corresponded 
to the melting point of lactose followed by its 
decomposition. This thermal behavior of lactose has 
been previously reported by Larhrib et al (2003).
31
 The 
DSC curve of all tablets showed the characteristic peak 
of the PEG, without drug peak indicating that the drug 
was completely dissolved in the molten carrier during 
DSC measurement. Analogous phenomena have also 
previously been reported.
8,32,33
 Alteration of this drug in 
solid dispersion containing PEG as inert carrier has been 
reported previously by Zheng et al (2005).
34
 The 
exothermic peak of tablets containing 75 mg 
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indomethacin exhibited at 24.7 °C after reverse run to  
-30
 °C (cooling-down period). Because the system 
containing 75 mg indomethacin use a high amount of 
carrier, the carrier was recrystallized and the exothermic 
peak occurred.
35
 Our study also wished to investigate the 
melting behavior of drug in PEG base both in heating up 
and cooling down periods with DSC reverse run. The 
melted PEG could dissolve the drug at the molecular 
level, therefore there was no melting peak of the drug in 
heating-up period. The dispersion of drug in molecular 
level maintained in cooling-down period should remain 
and the melting point of the drug could not be detected. 
By comparisons, the DSC curves of tablets with or 
without talcum or lactose were not different. This result 
indicated that the hydrophobicity and hydrophilicity of 
fillers did not significantly affect the DSC curves of the 
system containing drug and PEG. Previous study 
developed by Verma et al (2005 b) claimed that talcum 
and lactose did not interact with the drug in the blend. 
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Figure 6 Differential scanning calorimetry (DSC) thermograms of talcum (A) and lactose (B) in a range of 25 °C 
to 300 °C compared with thermograms from reverse run (-30°C to 70°C) of 75-mg indomethacin tablet 
containing 5% xanthan gum and 35% talcum (C) or 35% lactose (D) (lower part of the curve = heating-up period; 
upper part of the curve = cooling down period).   
 
 
Cross section and surface topography of tablets  
From SEM micrographs of tablet containing 75 mg 
indomethacin and 5% xanthan gum indicated that most 
drugs should be molecular dispersed in the PEG 
4000:PEG 400 matrix (data not shown). The tablet 
containing 5% xanthan gum exhibited less porosity. The 
higher amount of PEG promoted the matrix erosion 
owing to its high solubility, therefore there was no 
sponge-like structure as exhibited in the case of a 
system containing higher amount of diluents such as, 
lactose and talcum (Fig. 7). However, the dissolved drug 
molecules could diffuse through the pore and the kinetic 
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profile of drug release should be the diffusion-controlled 
release.  
SEM photograph of tablets containing 35% talcum or 
35% lactose exhibited a large amount of pores after the 
240-min. dissolution test (Fig. 7). These pores occurred 
from the diffusion of drug due to the opening of the 
channels. Therefore, a large number of pores increasing 
with time were observed. In contrast, the drug release 
was decreased as the amount of talcum or lactose was 
increased. Consequently, the use of talcum or lactose in 
the tablet containing 5% xanthan gum diminished the 
drug dissolution and retarded the drug release. 
 
  
35% Talcum 35% Lactose 
  
(5 min) 
  
(30 min) 
  
(240 min) 
  
(480 min) 
    
Figure 7 SEM micrographs of tablet containing 75 mg indomethacin, 5% xanthan gum and 35% 
talcum or lactose after dissolution test in phosphate buffer pH 6.2 for 480 min at different 
time interval with a magnification of 250. 
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Analysis of the drug release data 
To analyze the in vitro release data, the curve fitting of 
drug dissolution profiles to various kinetic models were 
carried out to describe the release kinetics. The zero 
order kinetic describes the systems where rate of drug 
release is independent on its concentration.
37
 The first 
order describes the release from system where release 
rate is concentration dependent.
38
 Higuchi described the 
release of drugs from insoluble matrix as a square root 
of time dependent process based on Fickian diffusion. 
Fickian diffusional release and a case-II relaxational 
release are the limits of this phenomenon. Fickian 
diffusional release occurs by the usual molecular 
diffusion of the drug due to a chemical potential gradient. 
Case-II relaxational release is the drug transport 
mechanism associated with stresses and state-transition 
in hydrophilic glassy polymers which swell in water or 
biological fluids. This term also includes polymer 
disentanglement and erosion.
39
 
The r
2
 from curve fitting to power law equation was in 
a range of 0.9885 to 0.9989 and msc was in range of 
3.10 to 6.23 (Table 4). For curve fitting of the drug 
release with different rotational speeds to power law 
equation, the r
2
 was in a range of 0.9823 to 0.9979 and 
msc was in a range of 3.63 to 5.25 (Table 5). The data 
of cumulative drug releases that were not adequate to be 
determined by curve fitting were designated as "not 
determined".  Typically, the extent of release at the initial 
and late periods varied largely between inter- and intra-
drug-carrier dispersions. Therefore, modeling analysis 
was carried out by fitting the dissolution data of 5 - 80% 
of the drug released.  
 
 
Table 4 Comparison of degree of goodness-of-fit from curve fitting of drug dissolution profiles of tablets containing 
5%w/w xanthan gum and different amount of diluent in 70:30 PEG4000:PEG400 to different release models. 
Power law First order HiguchiBs Zero order 
Formula 
r
2
 msc r
2
 msc r
2
 msc r
2
 msc 
75-mg indomethacin capsule  0.9913 4.16 0.9955 2.98 0.9811 3.51 0.9915 4.23 
5 % xanthan gum 0.9985 5.95 0.8996 1.90 0.8560 1.54 0.7572 1.02 
Small tablet with 5% xanthan gum  0.9895 4.09 0.9793 3.54 0.9839 3.80 0.9460 2.59 
Small tablet without xanthan gum  0.9984 5.76 0.9980 5.77 0.9988 3.51 0.9965 5.21 
Medium tablet with 5% xanthan gum  0.9985 3.10 0.8996 1.90 0.8560 1.54 0.7572 1.02 
Medium tablet without xanthan gum  0.9966 3.99 0.8468 1.08 0.9811 3.41 0.7082 0.43 
Large tablet with 5% xanthan gum  ND ND ND ND ND ND ND ND 
Large tablet without xanthan gum  ND ND ND ND ND ND ND ND 
15 % talcum 0.9886 4.01 0.9396 2.50 0.9676 3.12 0.9206 2.23 
25 % talcum 0.9902 4.33 0.9808 3.62 0.9660 3.05 0.9803 3.59 
35 % talcum 0.9947 4.63 0.9909 4.30 0.9878 4.00 0.9847 3.78 
45 % talcum 0.9985 5.95 0.9771 3.38 0.9985 6.10 0.9694 3.09 
55 % talcum 0.9895 3.89 0.9436 2.43 0.9877 3.95 0.9607 2.79 
15 % lactose 0.9898 4.13 0.9577 3.10 0.9597 3.26 0.9667 3.10 
25 % lactose 0.9969 5.27 0.9956 5.12 0.9549 2.77 0.9965 5.33 
35 % lactose 0.9989 6.23 0.9976 5.65 0.9301 2.30 0.9988 6.37 
45 % lactose 0.9959 5.27 0.9981 5.87 0.9641 2.93 0.9991 6.64 
55 % lactose 0.9897 3.83 0.9030 1.83 0.9886 3.97 0.9890 4.52 
Note: ND = Not Determined  
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Table 5 Comparison of degree of goodness-of-fit from curve fitting of drug dissolution profiles of tablet containing 75-
mg indomethacin and 5% xanthan gum in phosphate buffer pH 6.2 at various rotational speed of basket to 
different release models.  
Power law First order HiguchiBs Zero order Rotational speed of basket 
(rpm) r
2
 msc r
2
 msc r
2
 msc r
2
 msc 
25  0.9952 4.75 0.9813 3.69 0.9873 4.08 0.9587 2.90 
50  0.9823 3.63 0.9226 2.29 0.9469 2.67 0.8992 2.03 
100  0.9979 5.25 0.8996 1.90 0.8560 1.54 0.7572 1.02 
150  ND ND ND ND ND ND ND ND 
Note: ND = Not Determined  
 
The exponent (n) values for most formula are shown in 
Tables 6 - 7. The magnitude of the exponent n could 
indicate various release mechanisms. In the present 
study (cylindrical shape) the limits considered were n = 
0.45 (indicating a classical Fickian diffusion-controlled 
drug release) and n = 0.89 (indicating a case II 
relaxational release transport, the polymer relaxation 
controls drug delivery). Values of n between 0.45 and 
0.89 can be regarded as indicators of both phenomena 
(transport corresponding to coupled drug diffusion in the 
hydrated matrix and polymer relaxation), commonly 
called anomalous non-Fickian transport.
40
 The k value 
can be regarded as power law release constant with 
bigger values leading to faster drug release. 
Mathematically, increase in n values bigger than 1.0 
would allow for a more desirable incremental release. To 
achieve a delayed release pattern that was therapeutic-
ally useful, n values were expected to be bigger and k 
values to be smaller with a prerequisite of acceptable lag 
time.
41 
 
 
Table 6 Estimate parameter from curve fitting of drug dissolution of tablets containing 5% w/w xanthan gum and 
different amount of diluent in 70:30 PEG 4000:PEG 400 to power law expression.  
Formula k ± sd x 10
-1
  n ± sd 
Capsule containing 75-mg indomethacin 0.1232 ± 0.0208 0.31 ± 0.05 
5% xanthan gum 0.0098 ± 0.0011 0.51 ± 0.02 
Small tablet with 5% xanthan gum  0.0123 ± 0.0115 0.35 ± 0.04 
Small tablet without xanthan gum  0.0035 ± 0.0028 0.29 ± 0.06 
Medium tablet with 5% xanthan gum  0.0098 ± 0.0011 0.51 ± 0.02 
Medium tablet without xanthan gum  0.0074 ± 0.0272 0.33 ± 0.07 
Large tablet with 5% xanthan gum  ND ND 
Large tablet without xanthan gum  ND ND 
15% talcum 0.0532 ± 0.0063 0.33 ± 0.02 
25% talcum 0.0122 ± 0.0021 0.28 ± 0.14 
35% talcum 0.0058 ± 0.0023 0.64 ± 0.06 
45% talcum 0.0098 ± 0.0011 0.31 ± 0.02 
55% talcum 0.0123 ± 0.0046 0.43 ± 0.06 
15% lactose 0.0167 ± 0.0042 0.52 ± 0.04 
25% lactose 0.0011 ± 0.0005 0.92 ± 0.07 
35% lactose 0.0008 ± 0.0002 0.97 ± 0.05 
45% lactose 0.0032± 0.0012 0.91 ± 0.05 
55% lactose 0.0050 ± 0.0038 0.58 ± 0.12 
 Note: ND = Not Determined  
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Table 7 Estimate parameter from curve fitting of drug 
dissolution from tablet containing 75-mg 
indomethacin and 5% xanthan gum in 
phosphate buffer pH 6.2 at various rotational 
speed of basket to power law expression.  
Rotational speed of 
basket (rpm) 
k ± sd x 10
-1
 n ± sd 
25  0.0312 ± 0.0075 0.37 ± 0.03 
50  0.0804 ± 0.0081 0.29 ± 0.02 
100  0.0108 ± 0.0081 0.41 ± 0.02 
150  ND ND 
Note: ND = Not Determined 
 
The release kinetics of tablets containing xanthan 
gum, tablets containing different amounts of talcum in 
xanthan gum matrix tablet, tablets with different sizes 
followed a square root of time according to the Higuchi7s 
model. This was because Fickian diffusion occurred via 
the porous network that was formed when indomethacin 
dissolved from the inert matrix. During contaction 
between xanthan gum matrix and dissolution medium, 
the macromolecular chains swelled at the tablet surface 
and formed a gel layer around a dry-like core. Drug 
diffusion occurred at the core-gel interface then through 
this gel.
42
 Erosion of swollen layer along with dissolution 
of the matrix itself was also observed. The drug release 
data were explored for the type of release mechanism 
followed. For controlled or sustained release 
formulations, diffusion, swelling and erosion were the 
three most important rate controlling mechanisms. The 
drug release from the polymeric system was mostly by 
diffusion and was best described by Fickian diffusion. 
In vitro release data of tablets containing different 
amounts of lactose in xanthan gum matrix exhibiting the 
best fitted to zero order model with n value close to 0.84 
hence they exhibited a Case-II transport.
43
 These results 
were in agreement with the ones published by Sujja-
areevath et al (1998)
44
 that established correlation 
among the swelling, erosion and drug release in 
hydrophilic matrices elaborated from natural gums as 
xanthan, karaia and locust bean gum. An addition of 
hydrophilic lactose might adjust the erosion and the 
swelling of matrix, therefore there was the modulation of 
the drug diffusion from matrix component into dissolution 
fluid to obtain the constant drug release rate. By 
comparison there was the apparent evidence of more 
erosion of matrix containing lactose than the matrix 
containing talcum as shown in Fig. 7. The n values of 
tablets containing 75 mg indomethacin and 5% xanthan 
gum obtained from dissolution test with different 
rotational speeds of basket were fitted well with Higuchi7s 
model. Therefore, the release mechanism of these 
tablets was close to Fickian transport.   
 
Conclusion  
Amount of PEG played an important role in 
enhancement of dissolution of indomethacin, therefore an 
increase of the size of tablet increased the drug 
dissolution. An addition of diluents such as talcum and 
lactose which decreased the carrier amount promoted 
the decrease of drug dissolution from PEG matrix. Curve 
fitting indicated the drug release kinetics of most 
developed tablets primarily as Fickian diffusion from the 
matrix systems except that tablets using lactose as 
diluent followed near zero-order kinetic profile.  
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